Zachary Quinn

ORCID: 0000-0002-7688-2914
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Extracellular vesicles in disease
  • Biosensors and Analytical Detection
  • SARS-CoV-2 detection and testing
  • RNA Interference and Gene Delivery
  • Advanced biosensing and bioanalysis techniques
  • Cancer Immunotherapy and Biomarkers
  • MicroRNA in disease regulation
  • Nanoplatforms for cancer theranostics
  • Immunotherapy and Immune Responses
  • Medical Imaging and Pathology Studies
  • SARS-CoV-2 and COVID-19 Research
  • Epigenetics and DNA Methylation
  • MXene and MAX Phase Materials
  • Microfluidic and Bio-sensing Technologies
  • Ferroptosis and cancer prognosis
  • Cell Adhesion Molecules Research

Pratt Institute
2021-2023

Duke University
2021-2023

Binghamton University
2019-2020

Highly sensitive, specific, and point-of-care (POC) serological assays are an essential tool to manage coronavirus disease 2019 (COVID-19). Here, we report on a microfluidic POC test that can profile the antibody response against multiple severe acute respiratory syndrome 2 (SARS-CoV-2) antigens-spike S1 (S1), nucleocapsid (N), receptor binding domain (RBD)-simultaneously from 60 μl of blood, plasma, or serum. We assessed levels antibodies in plasma samples 31 individuals (with longitudinal...

10.1126/sciadv.abg4901 article EN cc-by-nc Science Advances 2021-06-25

Triple negative breast cancer (TNBC) is a heterogeneous subset of characterized by its lack estrogen receptor, progesterone and human epidermal growth factor receptor 2 (HER2), which altogether prevents TNBC from being treated effectively. For many years, the treatment paradigms overall survival patients with have remained largely stagnant. Recent attempts to convert cold tumors hot promoting antigen presentation shown increased T cell infiltration significantly induced immune responses for...

10.1016/j.bioactmat.2020.09.016 article EN cc-by-nc-nd Bioactive Materials 2020-09-25

Extracellular vesicles (EVs) are cell-released of submicrometer size. EVs contain a tissue-specific signature wherein variety proteins and nucleic acids selectively packaged. Recent studies validate that can be used for cancer diagnostics, staging, treatment monitoring. EV-related clinical translation requires effective EV isolation as prerequisite. However, lengthy procedures, low yield, throughput, high levels contaminants disqualify the existing approaches large-scale use. Hence, new...

10.1021/acs.analchem.9b03064 article EN Analytical Chemistry 2019-10-09

Cancer derived extracellular vesicles can be specifically and efficiently isolated by multivalent aptamers which are prepared rolling cycle amplification for downstream molecular analyses.

10.1039/d0an01420f article EN The Analyst 2020-10-07

Antigen tests to detect SARS-CoV-2 have emerged as a promising rapid diagnostic method for COVID-19, but they are unable differentiate between variants of concern (VOCs). Here, we report point-of-care test (POC-T), termed CoVariant-SPOT, that uses set antibodies either tolerant or intolerant spike protein mutations identify the likely strain concurrent with COVID-19 diagnosis using targeting nucleocapsid protein. All reagents incorporated into portable, multiplexed, and sensitive platform...

10.1021/acs.analchem.2c05180 article EN Analytical Chemistry 2023-03-24

Direct measurement of the small extracellular vesicle in cell culture supernatant.

10.1039/d0an01199a article EN cc-by-nc The Analyst 2020-01-01

GIMAPs are recognized as an important regulator in the carcinogenesis and development of lung cancer, but function GIMAP4 tumor microenvironment (TME) cancers is unclear. In this study, we investigated expression variation adenocarcinoma (LUAD), to explore its association with infiltration immune cells. The Cancer Genome Atlas (TCGA) data Gene Expression Omnibus (GEO) were analyzed. Infiltration cells was identified TIMER (Tumor Immune Estimation Resource) TISIDB (an integrated repository...

10.1155/2022/7440189 article EN cc-by BioMed Research International 2022-10-06
Coming Soon ...